The FDA will review both Medicis Pharmaceutical Corp.'s Restylane and Inamed Corp's Hylaform on November 21.
Evaluating Efficacy of Trifarotene in Latin American Patients With Acne
The Cutaneous Connection: Exploring the Effects of Pollutants on Atopic Dermatitis
Understanding Eyebrow and Eyelash Hair Loss in Severe Alopecia Areata
The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques
Data-Driven Advice for Health Care Workers Experiencing Contact Dermatitis
Prolonged Remission in Rosacea: A Breakthrough With Subantibiotic Dose of Oral Doxycycline
2 Clarke Drive Cranbury, NJ 08512